Regula Becomes the First to Verify All Dynamic Security Features in Remote Document Checks
22.4.2025 13:00:00 EEST | Business Wire | Press release
With the recent update of its Document Reader SDK, Regula became the first identity verification (IDV) vendor to make it possible to verify all the dynamic security features of documents in real time. With the latest addition of Dynaprint® checks, the solution ensures more robust physical document authentication during remote onboarding. The innovation has arrived at a time when 58% of businesses globally face fake or modified IDs during digital onboarding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422724077/en/
Dynaprint in the Arizona’s driver’s license (Photo: Regula)
Dynaprint® is a dynamic security feature consisting of two different images printed with lenticular technology. Depending on the angle of observation, only one image is visible at a time. Like all other dynamic security features, Dynaprint is crucial for securing identity documents from tampering, since it’s a tricky task to fake it without special equipment. Previously, it was feasible to verify Dynaprint only on-site with the help of special equipment. However, Regula has made it possible to check it online via a smartphone to ensure you are dealing with a live physical ID.
At the moment, Regula Document Reader SDK is the only IDV solution on the market that supports major dynamic security features, including Dynaprint®, for document liveness verification. At the moment, no other vendor features this level of protection for remote document checks.
This enhancement complements existing checks for other visible dynamic security features, such as holograms, optically variable inks (OVI), and multiple laser images (MLI). By prioritizing document liveness checks in its solution, Regula helps businesses and government institutions combat a wide range of presentation attacks, such as screen replays, injections, and printouts, and effectively detect manipulated IDs.
“With every update, our goal is to raise the bar for what reliable identity verification looks like. The addition of Dynaprint® checks in our Regula Document Reader SDK is more than a technical upgrade—it’s a significant enhancement in verifying the physical presence of an ID. When dynamic features like this are validated in real time, it becomes nearly impossible for fraudsters to succeed with deepfakes or static document copies,” says Ihar Kliashchou, Chief Technology Officer at Regula.
What else is new?
Alongside improved liveness verification, this update to Regula Document Reader SDK also included support for 432 new identity documents, bringing the total number to more than 15,000 documents from 251 countries and territories. Among them, for example, are the newest Japanese passport introduced in late March 2025, and the new Philippine National ID.
The latter brings a unique verification challenge: unlike other IDs, the Philippine National ID does not contain a handwritten signature, relying instead on an encrypted QR code with a digital signature to prove document integrity. While the QR code can be verified via the governmental portal, Regula Document Reader SDK offers a more robust and comprehensive solution for checking the ID’s authenticity. It ensures that the encoded information hasn’t been altered in any way, and that the digital signature is valid. Additionally, Regula’s solution performs multiple in-depth checks, cross-validating data from various document zones, and reading both visible and encrypted data.
Explore how Regula’s Dynaprint® verification can elevate your identity verification workflows on Regula’s website.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422724077/en/
Contacts
Kristina – ks@regulaforensics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom